PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.
Clinical trial NCT05207735 · UNKNOWN
Trial details
- NCT number
- NCT05207735
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-01
- Primary completion
- 2023-12-01
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.